Your Education
Atlas of Stains
Events and Webinars
All Resources
eIFUs
Contact CDx Team
CPS
Your Education
Atlas of Stains
Events and Webinars
All Resources
eIFUs
Contact CDx Team
CPS
Non-Small Cell Lung Cancer (NSCLC)
Indication-specific training resources to support high-quality diagnostic assessment of NSCLC specimens stained with PD-L1 IHC 22C3 pharmDx.
PD-L1 IHC 22C3 pharmDx Interpretation Training Program for Non-Small Cell Lung Cancer (NSCLC)
View More
PD-L1 IHC 22C3 pharmDx Interpretation Manual for Non-Small Cell Lung Cancer (NSCLC)
View More
PD-L1 IHC 22C3 pharmDx Quick Scoring Guide for Non-Small Cell Lung Cancer (NSCLC)
View More
PD-L1 Staining in Non-small Cell Lung Cancer (NSCLC) cases
View More
The PD-1/PD-L1 Pathway
View More
The development of a CDx IHC Assay
View More
What is a CDx IHC Assay?
View More
PD-L1 IHC 22C3 pharmDx and NSCLC One Assay, Two Platforms
View More
The Nuances of Tumor Types: How are Cutoffs Determined and Validated?
View More
Implementation of PD-L1 Testing in the New Era of an Everchanging Immuno-oncology Landscape
View More
The Pathologist and the Oncologist Working Together on PD-L1 to Improve Patient Treatment
View More
External Quality Assurance of PD-L1 Assays The NordiQC Experience
View More
The Rationale Behind the Scoring Systems for PD-L1 IHC to Determine Patients Eligible for KEYTRUDA (pembrolizumab)
View More
The Value of CDx IHC Assays in the Complex Environment of PD‑L1 Testing
View More
D72731_01